•     By Jason Derry —

    Reliance Life Sciences
    Reliance Life Sciences has
    announced that it will buy a controlling share of GeneMedix Plc.  UK-based
    GeneMedix is a biopharmaceutical company whose core technology involves
    "protein development scale-up and manufacture" (see link).  Reliance Life Sciences, based in India, "is developing business
    opportunities in the domains of medical biotechnology, plant biotechnology,
    industrial biotechnology, clinical research services and contract
    manufacturing" (see link).  Reliance's investment is reported to be $63.2
    million.

    GeneMedix
    Jason Derry, Ph.D., who graduated with honors from DePaul University
    College of Law, is a molecular biologist and founding author of Patent Docs.

  •     By Christopher P. Singer

    USPTO Seal
    The USPTO presented a seminar today, December 20, 2006,
    that provided an overview of the new features now available on Private PAIR and
    announced the new Priority Document Exchange program (PDX).  The presentation has been recorded and will
    be available within 48 hours at http://webex.client.ninesystems.com/pair122006.

    Private PAIR 7.0

    Some of the new features highlighted during the
    presentation included:

    • Pending non-published PCT application search.  A new button has been added for a search
    based on PCT application number.  PAIR provides application data,
    transaction history, attorney address, and an image file wrapper.  It is important to remember to associate
    a customer number with your PCT application.  This can be done through EFS-Web or by submitting a form letter to EBC.

    • XML Application Data Download provides for downloadable
    bibliographic application data, which can be used for document mapping and
    integrated into many docketing and document management systems.  The XML download is presented as an orange
    button usually next to "search" button.

    • Self-administration of Customer Number allows for
    on-line changing of correspondence information or a list of attorneys associated
    with the customer number.  Further,
    practitioners can search for application status changes by customer number (as
    far back as 180 days).

    • Self-administered Attorney Docket Number allows
    practitioners to edit a docket number on PAIR's bibliographic application data
    page.

    • Ordering certified copies of pending applications and
    certified file histories.

    • Cited reference display enhancements provide a list of
    cited references in three sections: U.S. Patent Documents, Reference Forms
    (e.g., PTO1449 forms), and Foreign Patents and NPLs.  All cited references are downloadable.

    Priority Document Exchange (PDX)

    EPO-EPC
    The USPTO indicates this program will allow for the free
    electronic exchange of documents between the U.S. and European Patent
    Offices.  The request can be made using
    a PTO form (PTO/SB/38), which provides a
    release for non-published U.S. Applications.  After placing the request, you should monitor Private PAIR for confirmation
    of the application transmission.  Request
    instructions can also be found at the EPO's website.  The request can be made through EFS-Web,
    through U.S. Mail, or by fax to the USPTO's Central Fax Number (571-273-8300).  You can request additional information
    regarding this program by e-mail to PDX@USPTO.gov.  The PDX program is expected to expand to
    include the Japanese Patent Office in June 2007.

  •     By Christopher P. Singer

    Pfizer
    In a December 19, 2006 press release, Pfizer Inc.
    announced that its Australian patent AU 601,981 covering atorvastatin (the
    active ingredient in Lipitor®) was upheld by the Australian Federal Court in
    Victoria.  The ruling concluded Ranbaxy's 2005 lawsuit and imposes an injunction
    against Ranbaxy's generic product.  The
    601,981 patent is in effect through May 2012.

    Ranbaxy
    The court ruled against Pfizer concerning its AU 628,198
    patent covering the atorvastatin calcium salt, holding that patent to be
    invalid.

    Each decision can be appealed.

    Atorvastatin_lipitor_2

     

  •     By Jason Derry —

    Medimmune #1
    MedImmune, Inc. and Biowa,
    Inc.
    have announced a licensing and collaboration deal relating to development and
    commercialization of therapies for inflammatory diseases.  In particular, the agreement relates to
    treatments that target interleukin-5 receptor.  The companies have indicated that the initial focus will be on a
    monoclonal antibody, BIW-8405, which is in Phase I clinical trials with asthma
    patients.  BIW-8405 is a humanized
    monoclonal antibody that binds to the IL-5 receptor.  Biowa has developed the antibody using its
    POTELLIGENT® technology.

    Biowa
    Jason Derry, Ph.D., who graduated with honors from DePaul University
    College of Law, is a molecular biologist and founding author of Patent Docs.

  •     By Jason Derry —

    GENESIS Pharma
    Alfacell Corp. and GENESIS
    Pharma S.A.
    have announced an exclusive
    licensing deal involving Alfacell's lead compound, ONCONASE®.  The compound is in Phase IIIb clinical trials
    for the treatment of unresectable malignant mesothelioma. Under the agreement, GENESIS will receive the
    exclusive right to market and distribute ONCONASE® in Southeast Europe.  Alfacell is a biopharmaceutical company whose
    proprietary technology is ribonuclease therapeutics.  GENESIS Pharma is a pharmaceutical company
    focused on in-licensing, marketing, and distributing biotechnology products,
    particularly in Southeast Europe.

    Alphacell
    Jason Derry, Ph.D., who graduated with honors from DePaul University
    College of Law, is a molecular biologist and founding author of Patent Docs.

  •     By Christopher P. Singer

    Uspto_seal

    The USPTO has asked Patent Docs to remind its readers that the Patent Office announcement
    regarding Private PAIR 7.0 and the EDX program, originally scheduled for December 19th, has been rescheduled for today (December 20th) at 1:00 pm Eastern
    time.  The event can be accessed here.

  •     By Christopher P. Singer

    EFS-Web
    The U.S. Patent Office today announced that a limited
    group of Private PAIR users have been given the option of receiving electronic
    correspondence from the USPTO instead of paper mailings.  The December 19, 2006 notice discusses an
    overview of the program and says that depending on its success, it could be
    opened to all Private PAIR users (that is, registered practitioners with a
    customer number and access to Private PAIR) as early as June 2007.

    The pilot program will not include correspondence from
    certain Office departments, including the Office of Initial Patent Examination,
    Petitions, PCT, Appeals, Publications, Interference, and Reexamination.  Once the program is in full effect, the PTO
    anticipates that a practitioner will sign up for the program and be able to
    associate from one to three e-mail addresses for notification purposes.  Once a practitioner opts into the program,
    the system will send a message to each e-mail address the practitioner lists,
    which will detail any Office correspondence generated within the past 24 hours
    for any patent or patent application associated with the customer number.

    For further details regarding this program, please refer
    to the notice, linked above.

  •     By Jason Derry —

    GlaxoSmithKline - GSK
    GlaxoSmithKline Plc. has announced a partnership with Genmab A/S relating to a particular
    antibody, HuMax-CD20, which is in late-stage clinical development for treating
    leukemia, lymphoma, and rheumatoid arthritis.  Under the agreement, GSK will give Genmab an upfront payment of $103
    million, and will purchase additional shares in the future, bringing the total
    potential value of the deal to $2.1 billion.

    GenMab

    The news follows GSK's recently announced acquisition of the antibody therapeutics company, Domantis Ltd.  In that deal,
    GSK agreed to buy Domantis for $454 million.

    Domantis

    Jason Derry, Ph.D., who graduated with honors from DePaul University
    College of Law, is a molecular biologist and founding author of Patent Docs.

  •     By Christopher P. Singer

    USPTO Seal
    Unfortunately, because of technical difficulties the U.S.
    Patent Office was unable to broadcast its presentation originally scheduled for
    1:00 pm EST today, regarding the update to Private PAIR (Private PAIR
    7.0).  They hope to reschedule the event
    for sometime tomorrow.

    Earlier today, the PTO announced that this presentation
    will also discuss the Priority Document Exchange System (PDX) that is scheduled
    to launch (with intent to have full capability) on January 16, 2007.  As we reported on November 24,
    the PDX program will allow an Applicant to request that the USPTO either
    request from or release to the EPO, an electronic version of a priority
    document.  This will be at no cost to the
    Applicant.  The current fee for
    requesting that the USPTO provide a priority document is $20 per document.

    This webcast will be recorded and available for later
    viewing.  We will provide that
    information as it becomes available.

  •     By Mark Chael

    AstraZeneca_small
    AstraZeneca's European Patent No. EP 0 652 872 related to
    Nexium® was reviewed on December 19, 2006 by the Boards of Appeal at the
    European Patent Office.  In 2003, this
    patent successfully survived an opposition filed by Ratiopharm GmbH of
    Germany.  However, appeal no. T0401/04
    was received on March 16, 2004, a Statement of Grounds of Appeal was filed on
    July 6, 2004, and thereafter Oral Proceedings were scheduled for December
    19, 2006.

    According to Reuters, opinions are mixed whether this
    final decision will go for or against AstraZeneca.  In 2005, Nexium® accounted for about $4.6 billion (US) to
    AstraZeneca's bottom line.  Currently, AstraZeneca
    is engaged in a patent infringement lawsuit related to Nexium® in the
    District of New Jersey (#3:05-cv-05553-JAP-TJB) against a number of defendants,
    including Ranbaxy, Ivax, Zenith, and Teva.

    Undoubtedly, the European Appeal of EP 0652872 is being
    closely watched by the defendants in that case.  U.S. Patent Nos. 5,714,504; 5,877,192; and 6,875,872 are all members of
    the same patent family as EP 0 652 872.  The U.S. patents are listed in the U.S. FDA's Orange Book as covering
    Nexium® capsules.  However, due to the
    differences in patent laws and practice across the pond, the impact of the
    European appeal on the U.S. litigation may be little or none.